Medical News

RSS

African leaders to meet in Zambia to discuss country responses to HIV/AIDS

Later this month, "[f]our former heads of state and other high-level African leaders who are the champions for a HIV/AIDS-free generation project" will travel to Zambia at the request of Zambian President Rupiah Banda for a meeting to discuss ways to strengthen the HIV/AIDS response in Africa, Times of Zambia/allAfrica.com reports.

5 Oct 2010

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Neuro-Biotech Corporation introduces a Neuro-biomarker which is linked to a series of Neuro-Bio tests. This will permit to understand the science behind them and how they each will contribute to a progressive clinical investigation involving the input and output of the brain.

5 Oct 2010

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

CPS recommends all Canadian babies should be vaccinated against rotavirus

All Canadian babies should be vaccinated against rotavirus, according to a new statement by the Canadian Paediatric Society. The CPS is also calling for public funding of the vaccine, which is not currently covered by provincial or territorial health plans.

5 Oct 2010

U.S. Social Security Administration selects Accenture to implement emerging technology applications

The U.S. Social Security Administration (SSA) has selected Accenture as a prime contractor under the Information Technology Support Services Contract (ITSSC) that will be used to acquire a wide range of IT systems development and modernization services. The ITSSC includes a one-year base period plus six additional one-year options with an aggregate ceiling valued at $2.8 billion.

5 Oct 2010

FDA approves Food Contact Notification for CDG Solution 3000

The FDA notified CDG Environmental, LLC on September 29th of its approval of Food Contact Notification FCN 001011 for CDG Solution 3000 effective October 28, 2010.

5 Oct 2010

AmeriCares, AstraZeneca enter commitment to expand breast cancer treatment in Cambodia

AmeriCares and AstraZeneca Pharmaceuticals have made a three-year commitment to expand early breast cancer detection and treatment in Cambodia in hopes of increasing survival rates.

5 Oct 2010

Aeras Global receives FDA grant to develop biomarkers for TB vaccine

The Aeras Global TB Vaccine Foundation is pleased to announce receipt of a grant from the United States Food and Drug Administration (FDA) to develop new biological and immunological biomarkers for TB vaccine development. The FDA grant, which supports the coordination of a multi-investigator project with researchers from the United States, the United Kingdom and South Africa, will provide $362,102 in the first year of funding.

5 Oct 2010

American Anesthesiology acquires Southeast Anesthesiology Consultants

American Anesthesiology, a subsidiary of MEDNAX, Inc., today announced the acquisition of Southeast Anesthesiology Consultants, P.A., a physician group practice that provides anesthesia care and pain management services at nine hospitals, 12 ambulatory surgery centers and 10 pain management centers principally located in the Charlotte, NC, metropolitan area.

5 Oct 2010

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Celldex Therapeutics, Inc. today announced that the Company presented initial clinical data on CDX-1401 at the 25th Annual Meeting of the International Society of Biological Therapy of Cancer (iSBTc) in Washington, DC. CDX-1401 is a novel antibody-based targeted cancer vaccine candidate being evaluated as a treatment for patients with melanoma and other cancers that are known to express the tumor antigen NY-ESO-1.

5 Oct 2010

Elsevier launches new journal on neuroscience

Elsevier, a world-leading publisher of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new journal, Developmental Cognitive Neuroscience.

5 Oct 2010

Delta Health introduces ClinicalVirtuoso solution to optimize homecare therapist

In response to the growing homecare and therapy markets, and the importance of "aging-in-place" as an alternative solution to institutionalized care, Delta Health Technologies, LLC today announced the introduction of ClinicalVirtuoso the first clinical solution developed to optimize the homecare therapist.

5 Oct 2010

FDA awards $2.9 million to support tuberculosis research projects

The U.S. Food and Drug Administration today announced the award of $2.9 million to support six research projects that will help with the diagnosis, treatment, and prevention of tuberculosis (TB).

5 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

Terminal metastatic cancer effectively treated in mice

Terminal metastatic cancer - the presently untreatable cause of the great majority of all cancer deaths - has now been effectively treated in three common fatal cancers in mice, announced Genomic Systems, citing research published online today in the Proceedings of the National Academy of Science (PNAS).

5 Oct 2010

Opinions: MDGs; Obama's development policy; PEPFAR in Uganda

In a SciDev.Net editorial, David Dickson, director of SciDev.Net, examines progress towards the Millennium Development Goal (MDG) targets, highlighting their usefulness as well as their shortcomings. "The value of the MDGs lies in the way they have acted as both a carrot and a stick to focus the efforts of both development agencies and governments of developing countries," according to Dickson, who writes that "the curse of the MDGs is that they focus on relatively short-term, concrete objectives, and lack sufficient 'buy-in' from the very countries they are intended to help.

5 Oct 2010

NIEHS awards grant to study environmental impact on genetic information

The National Institute of Environmental Health Sciences has awarded $2.27 million to Indiana University researcher Joseph Shaw for a five-year study of how the environment alters genetic information through mutation and natural selection.

5 Oct 2010

Estech adds COBRA Revolution Bipolar Clamp to ablation product line

Estech, a leading provider of minimally invasive cardiac surgery devices, today announced the launch of its COBRA Revolution™ Bipolar Clamp for use in surgical ablation procedures. The new instrument enables deep transmural lesion formation after a single application and is the only clamp to feature reversible jaws, which uniquely allows surgeons to follow anatomic contours, for unprecedented ease of use and efficiency.

5 Oct 2010

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.

5 Oct 2010

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

4 Oct 2010

Medical News

African leaders to meet in Zambia to discuss country responses to HIV/AIDS

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

CPS recommends all Canadian babies should be vaccinated against rotavirus

U.S. Social Security Administration selects Accenture to implement emerging technology applications

FDA approves Food Contact Notification for CDG Solution 3000

AmeriCares, AstraZeneca enter commitment to expand breast cancer treatment in Cambodia

Aeras Global receives FDA grant to develop biomarkers for TB vaccine

American Anesthesiology acquires Southeast Anesthesiology Consultants

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Elsevier launches new journal on neuroscience

Delta Health introduces ClinicalVirtuoso solution to optimize homecare therapist

FDA awards $2.9 million to support tuberculosis research projects

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Terminal metastatic cancer effectively treated in mice

Opinions: MDGs; Obama's development policy; PEPFAR in Uganda

NIEHS awards grant to study environmental impact on genetic information

Estech adds COBRA Revolution Bipolar Clamp to ablation product line

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News